Pfizer’s US$11b gain from new tax lifts Q4 profit
Print Edition
PFIZER Inc beat analysts’ estimate for adjusted profit yesterday, helped by strong demand for its pneumonia vaccine Prevnar and rheumatoid arthritis drug Xeljanz, while reporting an US$11 billion gain from the new tax law.
The largest US drugmaker also forecast full-year earnings and revenue well ahead of Wall Street estimates and said it would invest about US$5 billion in the United States over the next five years.
The drugmaker said it would pay about US$15 billion in taxes over eight years to bring funds kept overseas back to the United States under the new tax laws.
Pfizer said the 2018 forecast reflected a full-year contribution from the consumer healthcare business, which the drugmaker plans to divest or spin-off this year.
The company said it booked a gain of US$11.34 billion from the new tax law, leading to a surge in fourth-quarter profit to US$12.27 billion, or US$2.02 per share.
Excluding the tax gain and other items, the company earned 62 cents per share. Revenue rose marginally to US$13.70 billion.
Analysts on average were expecting a profit of 56 cents per share and revenue of US$13.68 billion, according to Thomson Reuters.
Prevnar raked in sales of US$1.53 billion, up 8.3 percent from a year earlier, and above hopes of US$1.4 billion, according to consensus estimate from Barclays.
Xeljanz sales jumped 47.5 percent to US$410 million, beating estimates of US$393 million.
However, sales of the company’s breast cancer treatment Ibrance came below consensus estimate, despite an 11.4 percent increase to US$716 million.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
